Tristel PLC Study shows Tristel Wipes System benefits
October 12 2016 - 3:12AM
RNS Non-Regulatory
TIDMTSTL
Tristel PLC
12 October 2016
Tristel plc
("Tristel" or "the Company")
Comparison of high-level disinfectants for flexible
nasendoscopes published in
The Journal of Laryngology & Otology
Tristel plc (AIM: TSTL), the manufacturer of infection
prevention, contamination control and hygiene products, announces
that in a randomised, single-blind comparison of disinfectants used
in Ear, Nose and Throat clinics, its Wipes System proved to be the
equal in terms of microbiological efficacy to disinfectants
produced by Du Pont and Johnson & Johnson. In the study Du
Pont's PeraSafe peracetic acid disinfectant was used in a tray, and
Johnson & Johnson's Cidex OPA ortho phthalaldehyde disinfectant
was used in an automated washer-disinfector manufactured by
Medvators Inc. The Tristel Wipes System is a stand-alone process
requiring no equipment, support building services, or maintenance.
The study concluded that the Wipes System has no capital outlay
cost, the lowest running cost, the greatest convenience, and the
fastest turnaround time for medical instruments of the three
products evaluated.
The study, which was conducted by the Bay of Plenty District
Health Board, Tauranga, New Zealand in 2011 has been published in
the The Journal of Laryngology & Otology [Hitchcock, B.,
Moynan, S., Frampton, C., Reuther, R., Gilling, P. and Rowe, F.
(2016) 'A randomised, single-blind comparison of high-level
disinfectants for flexible nasendoscopes', The Journal of
Laryngology Otology, pp. 1-7. doi: 10.1017/S0022215116008860].
Preliminary results of the study were presented at the 11(th)
Congress for German Hospital Hygiene held in Berlin in March 2012,
and reported by an RNS Reach on 29 March 2012.
The Tristel Wipes System is a unique, patented decontamination
method for non-lumened scopes and probes. It has been a very
significant sales success for the Company globally. Worldwide sales
in the financial year ending June 2012 were GBP3.3m and are
expected to be GBP8.7m in the year ending June 2016.
Paul Swinney, CEO, comments: "We are pleased to see at long last
the publication in a peer-reviewed journal of this significant
study comparing our Wipes System with competitor products
manufactured by two of the world's major infection prevention
companies. The results affirm the key advantages of our Wipes over
alternative chemistries and disinfection methods. This is the
twenty-fifth peer-reviewed and published scientific paper featuring
Tristel products - a body of evidence of our products' attributes
that forms one of our Company's key strengths."
For further information please contact:
Tristel plc Tel: 01638 721 500
Paul Swinney, Chief Executive
Officer
Liz Dixon, Finance Director
Walbrook PR Ltd Tel: 020 7933 8780 or tristel@walbrookpr.com
Paul McManus Mob: 07980 541 893
Lianne Cawthorne Mob: 07584 391 303
finnCap Tel: 020 7600 1658
Geoff Nash/ Giles Rolls (Corporate
Finance)
Stephen Norcross (Corporate
Broking)
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAAKBDKOBDKPKD
(END) Dow Jones Newswires
October 12, 2016 03:12 ET (07:12 GMT)
Tristel (LSE:TSTL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Tristel (LSE:TSTL)
Historical Stock Chart
From Apr 2023 to Apr 2024